Alkermes plc (NASDAQ:ALKS – Get Free Report) was the recipient of a large drop in short interest in January. As of January 15th, there was short interest totalling 10,740,000 shares, a drop of 14.1% from the December 31st total of 12,500,000 shares. Approximately 6.8% of the shares of the stock are short sold. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is currently 6.5 days.
Alkermes Price Performance
Shares of NASDAQ:ALKS opened at $31.91 on Friday. The company has a current ratio of 3.45, a quick ratio of 3.03 and a debt-to-equity ratio of 0.22. Alkermes has a 1 year low of $22.90 and a 1 year high of $32.88. The business has a fifty day simple moving average of $29.74 and a 200 day simple moving average of $28.25. The firm has a market cap of $5.16 billion, a price-to-earnings ratio of 16.36, a P/E/G ratio of 1.56 and a beta of 0.49.
Insider Buying and Selling at Alkermes
In other news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the completion of the sale, the director now owns 23,013 shares in the company, valued at approximately $732,964.05. This represents a 10.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Craig C. Hopkinson sold 10,471 shares of the stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total value of $309,208.63. Following the sale, the executive vice president now owns 99,238 shares of the company’s stock, valued at $2,930,498.14. This trade represents a 9.54 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 147,738 shares of company stock valued at $4,572,904. 4.89% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Alkermes
Analysts Set New Price Targets
ALKS has been the subject of a number of research analyst reports. JPMorgan Chase & Co. reduced their target price on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, October 25th. The Goldman Sachs Group reduced their target price on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a report on Friday, October 25th. Stifel Nicolaus upgraded Alkermes from a “hold” rating to a “buy” rating and increased their target price for the company from $25.00 to $36.00 in a report on Tuesday, November 5th. Piper Sandler restated an “overweight” rating and issued a $37.00 target price (down previously from $38.00) on shares of Alkermes in a report on Friday, October 25th. Finally, HC Wainwright restated a “neutral” rating and issued a $37.00 target price on shares of Alkermes in a report on Friday, October 25th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $36.00.
Read Our Latest Research Report on ALKS
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Recommended Stories
- Five stocks we like better than Alkermes
- Roth IRA Calculator: Calculate Your Potential Returns
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- EV Stocks and How to Profit from Them
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.